$QTTB News

Why Is Q32 Bio Stock Gaining Friday?

Q32 Bio Inks Securities Purchase Agreement With New, Current Institutional Investors For ~$55M Private Placement Of Common Stock, Pre-Funded Warrants

Mizuho Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $14

Cantor Fitzgerald Initiates Coverage On Q32 Bio with Overweight Rating

HC Wainwright & Co. Reiterates Buy on Q32 Bio, Maintains $13 Price Target

Q32 Bio Q1 EPS $(0.54) Beats $(0.68) Estimate

Q32 Bio Files Prospectus To Launch New $75M At-The-Market Offering Program

Q32 Bio shares are trading lower after the company announced that it entered into a controlled equity offering agreement with Cantor Fitzgerald for up to $14.2 million of shares.

Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive

Q32 Bio Files Prospectus To Offer And Sell Common Stock Up To $14.2M Through Cantor

Q32 Bio shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

Q32 Bio Q4 Adj. EPS $3.65 Beats $(0.98) Estimate, Sales $53.737M

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

HC Wainwright & Co. Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $13

Q32 Bio Prices $10.5M Registered Direct Offering At $3.90 Per Share And $3.8999 Per Pre-Funded Warrant Led By Institutional Investor

Q32 Bio Mark Iwicki Withdraws Resignation From Q32 Bio Board; Mark Iwicki To Remain Chair Of Board

This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?

Top Midday Gainers

Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal

Akebia Announces Establishment of Rare Kidney Disease Pipeline